Adipotide vs Survodutide
A side-by-side research comparison of Adipotide and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adipotide | Survodutide |
|---|---|---|
| Full name | Adipotide (FTPP / Prohibitin-Targeting Peptide) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | Phase 3 Clinical Trial |
| Mechanism | A fusion of a prohibitin-targeting peptide and a pro-apoptotic sequence. It binds prohibitin on the vasculature that feeds white fat, inducing apoptosis of those blood vessels, which starves fat cells and causes them to be resorbed. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | ~2.6 kDa | 4,500 Da (approximate) |
| Half-life | Short (hours) | 5-7 days |
| Bioavailability | Subcutaneous injection | High (SubQ) |
| Typical dose | Not established for human use | 0.6-6.0 mg |
| Frequency | Research protocols only | Once weekly |
| Route | Subcutaneous injection | Subcutaneous |
Adipotide reported benefits
- Rapid targeted white-fat reduction (animal models)
- Weight loss without appetite suppression
- Reversal of metabolic markers in obese primates
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.